These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
312 related articles for article (PubMed ID: 22233484)
1. Pharmacotherapy for breakthrough cancer pain. Mercadante S Drugs; 2012 Jan; 72(2):181-90. PubMed ID: 22233484 [TBL] [Abstract][Full Text] [Related]
2. The use of rapid onset opioids for breakthrough cancer pain: the challenge of its dosing. Mercadante S Crit Rev Oncol Hematol; 2011 Dec; 80(3):460-5. PubMed ID: 21215653 [TBL] [Abstract][Full Text] [Related]
3. Opioids for the management of breakthrough pain in cancer patients. Zeppetella G; Davies AN Cochrane Database Syst Rev; 2013 Oct; (10):CD004311. PubMed ID: 24142465 [TBL] [Abstract][Full Text] [Related]
4. A randomized, placebo-controlled study of a new sublingual formulation of fentanyl citrate (fentanyl ethypharm) for breakthrough pain in opioid-treated patients with cancer. Novotna S; Valentova K; Fricova J; Richterova E; Harabisova S; Bullier F; Trinquet F; Clin Ther; 2014 Mar; 36(3):357-67. PubMed ID: 24508417 [TBL] [Abstract][Full Text] [Related]
6. A randomized, double-blind, placebo-controlled study of fentanyl buccal tablets for breakthrough pain: efficacy and safety in Japanese cancer patients. Kosugi T; Hamada S; Takigawa C; Shinozaki K; Kunikane H; Goto F; Tanda S; Shima Y; Yomiya K; Matoba M; Adachi I; Yoshimoto T; Eguchi K J Pain Symptom Manage; 2014 Jun; 47(6):990-1000. PubMed ID: 24099893 [TBL] [Abstract][Full Text] [Related]
7. Evidence-based treatment of cancer-related breakthrough pain with opioids. Zeppetella G J Natl Compr Canc Netw; 2013 Mar; 11 Suppl 1():S37-43. PubMed ID: 23520185 [TBL] [Abstract][Full Text] [Related]
8. Newer generation fentanyl transmucosal products for breakthrough pain in opioid-tolerant cancer patients. Elsner F; Zeppetella G; Porta-Sales J; Tagarro I Clin Drug Investig; 2011; 31(9):605-18. PubMed ID: 21819159 [TBL] [Abstract][Full Text] [Related]
9. Fentanyl buccal tablet for the relief of breakthrough pain in opioid-tolerant adult patients with chronic neuropathic pain: a multicenter, randomized, double-blind, placebo-controlled study. Simpson DM; Messina J; Xie F; Hale M Clin Ther; 2007 Apr; 29(4):588-601. PubMed ID: 17617282 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Oral or Nasal Fentanyl for Treatment of Breakthrough Pain in Cancer Patients: A Systematic Review. Rogríguez D; Urrutia G; Escobar Y; Moya J; Murillo M J Pain Palliat Care Pharmacother; 2015 Sep; 29(3):228-46. PubMed ID: 26458018 [TBL] [Abstract][Full Text] [Related]
11. [Transmucosal fentanyl administration: sublingual, buccal, nasal - all the same? Treatment of breakthrough cancer pain]. Überall MA MMW Fortschr Med; 2017 Oct; 159(Suppl 6):15-22. PubMed ID: 29557092 [TBL] [Abstract][Full Text] [Related]
12. [A New Therapeutic Approach for Cancer-Related Breakthrough Pain - Focused on Oral Transmucosal Fentanyl]. Yomiya K; Kaneshima M; Kyosaka B; Warita E; Hosonuma R; Osato S Gan To Kagaku Ryoho; 2017 Apr; 44(4):289-293. PubMed ID: 28428506 [TBL] [Abstract][Full Text] [Related]
13. Fentanyl buccal tablets for breakthrough pain in highly tolerant cancer patients: preliminary data on the proportionality between breakthrough pain dose and background dose. Mercadante S; Ferrera P; Adile C; Casuccio A J Pain Symptom Manage; 2011 Sep; 42(3):464-9. PubMed ID: 21477977 [TBL] [Abstract][Full Text] [Related]
14. Fentanyl buccal tablet compared with immediate-release oxycodone for the management of breakthrough pain in opioid-tolerant patients with chronic cancer and noncancer pain: a randomized, double-blind, crossover study followed by a 12-week open-label phase to evaluate patient outcomes. Webster LR; Slevin KA; Narayana A; Earl CQ; Yang R Pain Med; 2013 Sep; 14(9):1332-45. PubMed ID: 23855816 [TBL] [Abstract][Full Text] [Related]
15. Oral trasmucosal fentanyl citrate for breakthrough pain treatment in cancer patients. Mercadante S Expert Opin Pharmacother; 2012 Apr; 13(6):873-8. PubMed ID: 22424558 [TBL] [Abstract][Full Text] [Related]
16. Fentanyl for breakthrough cancer pain: where are we? Meriggi F; Zaniboni A Rev Recent Clin Trials; 2013 Mar; 8(1):42-7. PubMed ID: 23259417 [TBL] [Abstract][Full Text] [Related]
17. Breakthrough pain management using fentanyl buccal tablet (FBT) in combination with around-the-clock (ATC) opioids based on the efficacy and safety of FBT, and its relationship with ATC opioids: results from an open-label, multi-center study in Japanese cancer patients with detailed evaluation. Takigawa C; Goto F; Tanda S; Shima Y; Yomiya K; Matoba M; Adachi I; Yoshimoto T; Eguchi K Jpn J Clin Oncol; 2015 Jan; 45(1):67-74. PubMed ID: 25381384 [TBL] [Abstract][Full Text] [Related]
18. A network meta-analysis of the efficacy of opioid analgesics for the management of breakthrough cancer pain episodes. Zeppetella G; Davies A; Eijgelshoven I; Jansen JP J Pain Symptom Manage; 2014 Apr; 47(4):772-785.e5. PubMed ID: 23981487 [TBL] [Abstract][Full Text] [Related]
19. The role of rapid onset fentanyl products in the management of breakthrough pain in cancer patients. Brząkała J; Leppert W Pharmacol Rep; 2019 Jun; 71(3):438-442. PubMed ID: 31003154 [TBL] [Abstract][Full Text] [Related]
20. A review of rapid-onset opioids for breakthrough pain in patients with cancer. Simon SM; Schwartzberg LS J Opioid Manag; 2014; 10(3):207-15. PubMed ID: 24944071 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]